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might indicate a worsening osteoarthritic disease could be observed with either ratio. This was also true for HP/LP. Conclusions: Biomarkers have proven valuable in many biological systems and clinical situations eg in gastroenterology, cardiology and oncology. Cartilage biomarkers are still under development coming close to clinical utility. In this study, measurements of HP and LP in the urine of rabbits after complete medial meniscectomy did not show any simple significant postoperative changes. This was true for the respective ratios. Thus we were not able to monitor the development of OA-like lesions of the articular knee joint in a simple manner with these markers. Such somehow negative findings are part of a research development which is still stimulating and will further our detailed knowledge of cartilage and its diseases. Purpose: The CTX II assay has been developed to examine the type II collagen telopeptide that is released from articular cartilage into the systemic circulation. In human osteoarthritis (OA) patients, the Urine Cartilaps ® ELISA has been reported to be useful in the prediction of the progression of OA. Since type II collagen is well conserved across species, this assay was modified by the manufacturers into the pre-clinical assay to allow for a broader measuring range of CTX-II concentrations in non-human urine. Horses are one of the few species in which adequate volumes of paired synovial fluid, serum, and urine samples can be collected and compared to allow correlation of this marker in these different fluids. This may lead to translational benefit to human OA patients. The purpose of this report was to validate the use of the Urine Pre-Clinical CTX II assay for use with equine urine for future use with equine models of OA.
URINE PRE-CLINICAL CTX II (CARTILAPS

Methods: Urine Pre-Clinical Cartilaps
® ELISAs (Nordic Bioscience Diagnostics) were used for this validation study according to manufacturer protocols. Internal quality control (QC) samples were prepared using the highest concentration standard provided by the manufacturer (99 ng/ml). To create QC samples, fresh urine was collected from 6 normal horses via catheterization. The samples were pooled together for further processing and analysis. Pooled samples were spiked with a known amount of standard to create samples with high, medium and low levels of CTX II. The QC samples were used to determine the precision, specificity, sensitivity, accuracy, linearity of dilution, and stability of this assay with equine urine. To ensure that the assay could detect different biological activity, 3 previously stored urine samples from normal and OA horses were analyzed. Results: Reproducibility of the standard curve was evaluated (n=6 plates) by computing mean optical density (OD) and percent coefficient of variation (% CV) at each standard concentration. The overall mean inter-assay CV of the standard OD values was 6.5% (range 1.6-24.4%). Samples exhibited acceptable intra-assay and inter-assay precision over 3 plates with an overall mean CV of 4.3% (range; 1.2-12.3%) and 7.2% (range; 4.7-9.7%), respectively. Parallelism and linearity of dilution of equine serum sample dilutions (1:2, 1:4, 1:8, and 1:10) were demonstrated (Figure 1 ). Lowest detection limit of the assay was determined to be 1.38 ng/ml. Percent recovery was 90% for high, 90% for medium, and 95% for low QC samples. There was no loss in the stability of the CTX II epitope out to 4 freeze/thaw cycles. Differences in biological activity were identified when examining 3 samples from normal (3.23 ± 0.38 ng/ml) and OA (2.25 ± 0.37 ng/ml) horses (P=0.03) (Figure 2) . . Differences in biological activity were identified when examining 3 samples from normal (3.23 ± 0.38 ng/ml) and OA (2.25 ± 0.37 ng/ml) horses. Significant differences between groups are represented as * P<0.05 using an unpaired t-test. Purpose: The purpose of this study was to compare two commercially available kits and an inhouse method for measuring Cartilage Oligomeric Protein (COMP) in human serum and assessing their utility as biomarkers of knee osteoarthritis (kOA). rated immediately and stored at -80°C until analysis. Care was taken to insure all samples had undergone the same limited number of freeze-thaws at the time of analysis. COMP concentrations were determined using 3 sandwich ELISA methods: an inhouse method utilizing MAb's 16F12 and 17C10; and separate commercially available kits from Biovendor (Modrice, Czech Rep.) and Anamar (Gothenburg, Sweden). The Biovendor kit utilized the same MAb's as the inhouse method. The inhouse method uses COMP purified from human cartilage as it's standard while Biovendor uses a recombinant human COMP (Gln21-Ala757). Anamar uses human serum as a standard and results are expressed as U/L instead of ng/ml. OA status was determined radiographically for each knee from posterior-anterior X-rays using the Synaflex positioning device, and a Kellgren-Lawrence (KL) grade of ≥ 2 in at least one knee was considered to be positive for kOA. Linear regression was used to compare the results from the three methods. COMP concentrations were ln transformed and one-way ANOVA was used to assess the associations between COMP concentrations and knee OA laterality. Results: Demographic and clinical characteristics are shown in Table 1 . Fifty percent had knee OA, and this was unilateral (1 knee) in 58% of those with kOA and bilateral (both knees) in 42% of those with kOA. Correlations between the methods (Fig.  1 
Conclusions: Conclusions: The Urine Pre-Clinical Cartilaps
A COMPARISON OF METHODS FOR MEASURING CARTILAGE OLIGOMERIC PROTEIN (COMP) IN HUMAN
Conclusions:
Correlation between the inhouse method and the Biovendor kit was excellent, as expected since they use the same MAb set. Correlation of the Biovendor or inhouse methods with the Anamar kit was not as robust. The large differences between mean values and ranges for the inhouse and Biovendor assays are probably due to differences in the standards used.
Only the inhouse and Biovendor methods showed a significant association with kOA. All results were unadjusted for BMI, ethnicity, or age, which may all be important confounders when using COMP as a biomarker of OA. On the basis of these results, the Biovendor COMP seems the best suited of the commercial kits as a biomarker for kOA.
